Total trials
1,045
Active
105
Phase 3
309
Total enrollment
973,579
Pipeline matrix
Showing 40 of 99 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Inebilizumab | — | — | — | 9 | |||
| Avacopan | — | — | 9 | ||||
| Standard of Care | — | — | — | 5 | |||
| XGEVA® | — | — | — | — | — | 1 | |
| Prolia® | — | — | — | — | — | 1 | |
| Prolia | — | — | — | — | — | 1 | |
| Routine Lipid Management | — | — | — | — | — | 1 | |
| Evolocumab | — | 39 | |||||
| Maridebart Cafraglutide | — | — | — | 20 | |||
| Tarlatamab | — | — | 16 | ||||
| Pembrolizumab | — | — | — | 16 | |||
| Xaluritamig | — | — | — | — | 7 | ||
| Blinatumomab | — | 27 | |||||
| Durvalumab | — | — | — | — | 5 | ||
| Apremilast | — | 41 | |||||
| Sotorasib | — | — | 15 | ||||
| Panitumumab | — | — | — | 34 | |||
| Carboplatin | — | — | — | 16 | |||
| Docetaxel | — | — | — | 10 | |||
| Abiraterone | — | — | — | 4 | |||
| Dazodalibep | — | — | — | — | — | 3 | |
| Nivolumab | — | — | — | — | 3 | ||
| Olpasiran | — | — | 9 | ||||
| Etelcalcetide | — | — | — | — | 11 | ||
| Bemarituzumab | — | — | — | 5 | |||
| Etoposide | — | — | — | 3 | |||
| Enzalutamide | — | — | — | 3 | |||
| Cabazitaxel | — | — | — | — | — | 2 | |
| ABP 234 | — | — | — | — | — | 2 | |
| Romiplostim | — | — | 19 | ||||
| Romosozumab | — | — | 17 | ||||
| Methotrexate | — | — | — | 14 | |||
| Pegloticase | — | — | — | — | 7 | ||
| Rocatinlimab | — | — | 12 | ||||
| ABP 206 | — | — | — | — | — | 2 | |
| Chemotherapy | — | — | — | — | 2 | ||
| Erenumab Dose 1 | — | — | — | — | — | 2 | |
| Erenumab Dose 2 | — | — | — | — | — | 2 | |
| Erenumab Dose 3 | — | — | — | — | — | 2 | |
| IV Placebo | — | — | — | — | — | 1 |
59 more active programs hidden
Next readouts
- 2022-08-02
- 2024-04-09
- 2024-05-28
- 2025-01-29
- 2025-03-28
- 2025-10-06
- 2025-10-14
- 2025-11-19
- 2025-11-20
- 2025-11-21
Top conditions
- Anemia46
- Rheumatoid Arthritis45
- Psoriasis40
- Cancer32
- Chronic Kidney Disease29
- Multiple Myeloma25
- Kidney Disease21
- Metastatic Colorectal Cancer21
Frequently asked questions about Amgen
- How many clinical trials does Amgen have on ClinicalTrials.gov?
- Amgen is listed as the lead sponsor on 1,045 clinical trials in ClinicalTrials.gov, 105 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Amgen's trials are in Phase 3?
- 309 of Amgen's trials are in Phase 3, spread across 99 active drug programs.
- What therapeutic areas does Amgen focus on?
- Amgen's most-studied conditions on ClinicalTrials.gov are Anemia, Rheumatoid Arthritis, Psoriasis, Cancer, Chronic Kidney Disease.
- When are Amgen's next clinical trial readouts?
- Amgen has 10 upcoming primary-completion readouts tracked here; the soonest is “Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).”, expected around 2022-08-02.